The regions classified as high risk for multiple resilience alerts
have increased from 3 to 5 in the last week
.
They are Emilia Romagna, Puglia, Abruzzo, Liguria and Marche.
The regions classified as moderate risk are 10 and 6 are those at low risk.
This is indicated by the table relating to the decision-making indicators of the weekly monitoring of the Istituto Superiore di Sanità (ISS) and the Ministry of Health on the progress of the Covid-19 epidemic.
The Regions in which the
occupancy rate of ordinary wards
by Covid-19 patients exceeded the alert threshold of 15% rose from 7 to 9.
They are Umbria (33.2%), Liguria (31.6%), Valle d'Aosta (28.4%), Friuli Venezia Giulia (22.9%), Emilia Romagna (19.4%%), Marche ( 18.6%), Abruzzo (18.5%%), Veneto (16.5%), Calabria (15.6%, value as at 7 December).
The occupation of intensive care is below the 10% threshold in all regions.
The highest values are in Liguria (7.1%), Friuli Venezia Giulia (6.7%) and Abruzzo (6.1%).
This is revealed by the table on the decision-making indicators of the ISS-Ministry of Health monitoring.
(HANDLE).
New
Covid-19 cases still down in a week
with -2.8% (compared to last week's drop of 0.7%) while deaths register +8% (it was +9.5%).
It emerges from the weekly data published by the Ministry of Health.
In the week of 2-8 December, the ministry notes, 221,154 new positive cases were recorded against 227,440 in the previous week and 686 (635 previous figure);
1,256,722 swabs with a variation of -5.2% compared to the previous week (1,324,969);
positivity rate of 17.6% with a change of 0.4% compared to the previous week (17.2%).
The task force for the Covid emergency of the European drug agency (EMA) warns that
the monoclonal antibodies authorized today may not be effective against the emerging strains
of SarsCov2.
Designed to neutralize the virus by binding to the spike protein, mutations can reduce the ability to bind to it.
Laboratory studies, explains the EMA, show that monoclonal antibodies targeted on the spike are poorly effective in neutralizing the Omicron BA.4.6, BA.2.75.2 and XBB strains and do not significantly neutralize the BQ.1 and BQ variants. 1.1, which should become dominant in the coming weeks.